What is the 13F Pro Quality Score for UTHR?

13F Pro ranks UNITED THERAPEUTICS Corp (UTHR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View UTHR's current score at https://13fpro.ai/research/UTHR (free sign-up required for the full ranking).

Where does 13F Pro source UTHR data?

All UNITED THERAPEUTICS Corp fundamentals and ownership data come directly from SEC EDGAR. UNITED THERAPEUTICS Corp files with the SEC under CIK 1082554. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is UTHR in?

UNITED THERAPEUTICS Corp (UTHR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives UTHR's revenue?

Per UNITED THERAPEUTICS Corp's latest 10-Q filed with the SEC on 2026-05-06, the biggest revenue drivers are: Tyvaso DPI ($330.3M, +9% YoY); Orenitram ($135.6M, +12% YoY); Nebulized Tyvaso ($127.2M, -22% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/UTHR.

What are UTHR's largest expenses?

UNITED THERAPEUTICS Corp's latest 10-Q reports these as the largest expense items: Selling, general, and administrative ($184.1M, +8% YoY); Research and development ($138.2M, -7% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is UTHR research updated on 13F Pro?

UTHR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

UNITED THERAPEUTICS Corp(UTHR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1082554 UTHR stock profile & AI dashboard →

13F Pro Quality Score

80.1/100

Rank #46 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

75.0/100

Profitability

92.5/100

Balance Sheet

93.8/100

Earnings Quality

51.8/100

Free Cash Flow

89.7/100

Institutional Flow

91.2/100

Revenue Scale

70.9/100

Dilution Risk

27.0/100

UTHR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for UNITED THERAPEUTICS Corp (UTHR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores UTHR at 80.1/100 on a 32-signal composite quality model, placing it at rank #46 of 2,879 stocks — the top 5% of the AI-ranked universe. UTHR scores in the top quartile across balance sheet strength (93.8), profitability (92.5), institutional flow (91.2). Shareholder dilution risk is elevated at 27.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), UNITED THERAPEUTICS Corp reports quarterly revenue of $781.5M, net income of $274.9M, an operating margin of 41.7%. Top institutional holders of UTHR by reported 13-F value include BlackRock,, Avoro Capital Advisors, WELLINGTON MANAGEMENT GROUP LLP, based on the most recent SEC filings. UTHR trades on the Nasdaq exchange and files with the SEC under CIK 1082554. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate UTHR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for UNITED THERAPEUTICS Corp directly from SEC EDGAR. UNITED THERAPEUTICS Corp's 13F Pro composite quality score has ranged between 8 and 86 since 2021, currently 80.1 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about UNITED THERAPEUTICS Corp

Quirks, history, and lore behind UTHR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · mid-cap · listed on Nasdaq · headquartered in Maryland.
2
The Numbers
Annual revenue of roughly $2 billion, yet it runs with an unusually small headcount for its size — a lean machine that prints serious margins by focusing on a single disease area.
3
The History
Founded in the late 1990s, the company was built from the ground up around one devastating condition — pulmonary arterial hypertension — by a founder with a deeply personal reason to cure it.
4
The Secret
Its founder and CEO is a transgender pioneer and futurist who also runs a separate company dedicated to xenotransplantation — growing human-compatible organs in pigs.
5
The Lore
The company's PAH drug franchise — including Remodulin and Tyvaso — dominates its niche, and it has invested heavily in 3D-printed lungs and regenerative medicine as its next frontier.
6
The Giveaway
CEO Martine Rothblatt founded it after her daughter was diagnosed with PAH — the company's ticker is UTHR and its name pairs a certain global adjective with the word for healing.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving UTHR's Business? Latest 10-Q Breakdown

AI-extracted from UNITED THERAPEUTICS Corp's 10-Q filed 2026-05-06 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

United Therapeutics reported Q1 2026 revenues of $781.5M, down 2% YoY, with Tyvaso DPI growth (+9%) offset by Nebulized Tyvaso decline (-22%), while executing $1.5B share repurchase and advancing pipeline programs including successful ADVANCE OUTCOMES and TETON trials.

Biggest Revenue Drivers

Total revenue: $781.5M-2% YoY

Tyvaso DPI$330.3M+9% YoY

Increase in quantities sold of $16.0M, plus modest price increase

Orenitram$135.6M+12% YoY

Increase in quantities sold of $10.2M

Nebulized Tyvaso$127.2M-22% YoY

Decrease in U.S. quantities sold of $33.3M and international decline, partially offset by price increase

Remodulin$126.6M-8% YoY

Decrease in quantities sold of $11.1M

Largest Expense Items

Selling, general, and administrative$184.1M+8% YoY

General and administrative costs up 7%; share-based compensation up 15%

Research and development$138.2M-7% YoY

Decrease in milestone payments for drug delivery devices, offset by increased personnel expenses

Watch Items from the Filing

Two distributors account for 87% of total revenues (52% and 35%), creating concentration risk. Distributor ordering patterns can cause revenue volatility unrelated to patient demand.
Nebulized Tyvaso revenues declined 22% YoY; pending FDA approval for IPF indication expected by summer 2026, but DME MACs must update local coverage determination, a process potentially exceeding one year.
Tyvaso DPI inventory reserve increased $39.2M in Q1 2026 due to $26.8M loss on commercial supply agreement; supply management risk could impact future cost of sales.
Sandoz litigation: $74.9M accrued liability through March 31, 2026; appeal pending before Third Circuit Court; unfavorable appellate outcome could increase exposure materially.
Successful ADVANCE OUTCOMES trial (ralinepag): 55% reduction in clinical worsening risk; NDA submission targeted summer 2026; positions ralinepag favorably vs. Uptravi ($1.9B global sales in 2025).

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$781.5M

Net Income

Q1 2026

$274.9M

Free Cash Flow

Q1 2026

$362.5M

Operating Margin

Q1 2026

41.7%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+36.7% YoY

$3.18BFY 2025

FY21 $1.69BFY22 $1.94BFY23 $2.33BFY25 $3.18B

Net Income

+35.5% YoY

$1.33BFY 2025

FY21 $475.8MFY22 $727.3MFY23 $984.8MFY25 $1.33B

Operating Income

+26.0% YoY

$1.49BFY 2025

FY21 $555.9MFY22 $979.7MFY23 $1.18BFY25 $1.49B

EPS (Diluted)

+40.6% YoY

$27.86FY 2025

FY21 $10.06FY22 $15.00FY23 $19.81FY25 $27.86

Total Assets

+9.9% YoY

$7.88BFY 2025

FY21 $5.17BFY22 $6.04BFY23 $7.17BFY25 $7.88B

Op. Cash Flow

+59.6% YoY

$1.56BFY 2025

FY21 $598.2MFY22 $802.5MFY23 $978.0MFY25 $1.56B

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$3.18B +36.7%	$2.33B +20.2%	$1.94B +14.9%	$1.69B +13.6%	$1.48B +2.4%	$1.45B
Net Income	$1.33B +35.5%	$984.8M +35.4%	$727.3M +52.9%	$475.8M	—	—
Operating Income	$1.49B +26.0%	$1.18B +20.9%	$979.7M +76.2%	$555.9M -6.4%	$593.6M +416.4%	$-187.6M
EPS (Diluted)	$27.86 +40.6%	$19.81 +32.1%	$15.00 +49.1%	$10.06 -12.8%	$11.54 +582.8%	$-2.39
Total Assets	$7.88B +9.9%	$7.17B +18.6%	$6.04B +16.9%	$5.17B +12.0%	$4.62B +17.9%	$3.91B
Operating Cash Flow	$1.56B +59.6%	$978.0M +21.9%	$802.5M +34.2%	$598.2M -20.8%	$755.7M +465.8%	$-206.6M

AI Insight: UTHR Ratio Trends

Operating margin compressed to 41.7% in Q1 2026, down 7.4pp from Q4 2025, signaling near-term profitability pressure despite sustained high net margins.

• Net profit margin spiked to 46.1% in Q4 2025 then fell to 35.2% in Q1 2026, a 10.9pp decline—largest quarterly swing in dataset.

• ROIC compressed from 23.6% in Q3 2025 to 20.1% in Q4 2025, then recovered slightly to 22.1% in Q1 2026, showing volatility.

• ROE fell from 20.6% in Q3 2025 to 18.6% in Q1 2026, a 2pp decline marking weakness in shareholder returns generation.

⚠ Q1 2026 operating margin at 41.7% is lowest in nine-quarter dataset; trend continuation would signal structural margin erosion.

⚠ ROA declined to 16.4% in Q1 2026 from 18.5% in Q4 2025—monitor if asset productivity deterioration persists.

Get alerted when UTHR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for UNITED THERAPEUTICS Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of UTHR

BlackRock, Inc.
$3.2B5,399,649 sh
Avoro Capital Advisors LLC
$1.6B2,630,000 sh
WELLINGTON MANAGEMENT GROUP LLP
$1.3B2,264,247 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.2B2,003,742 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.2B1,957,539 sh
STATE STREET CORP
$1.1B1,843,963 sh
RENAISSANCE TECHNOLOGIES LLC
$1.1B1,787,019 sh
GEODE CAPITAL MANAGEMENT, LLC
$729.9M1,233,029 sh
JANUS HENDERSON GROUP PLC
$514.0M866,930 sh
AQR CAPITAL MANAGEMENT LLC
$486.4M826,226 sh

Fund	Value	Shares
BlackRock, Inc.	$3.2B	5,399,649
Avoro Capital Advisors LLC	$1.6B	2,630,000
WELLINGTON MANAGEMENT GROUP LLP	$1.3B	2,264,247
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.2B	2,003,742
VANGUARD CAPITAL MANAGEMENT LLC	$1.2B	1,957,539
STATE STREET CORP	$1.1B	1,843,963
RENAISSANCE TECHNOLOGIES LLC	$1.1B	1,787,019
GEODE CAPITAL MANAGEMENT, LLC	$729.9M	1,233,029
JANUS HENDERSON GROUP PLC	$514.0M	866,930
AQR CAPITAL MANAGEMENT LLC	$486.4M	826,226

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put UTHR on your watchlist

Track score changes the day UNITED THERAPEUTICS Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is UTHR a good stock to buy?

13F Pro's AI-powered analysis of UNITED THERAPEUTICS Corp (UTHR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for UTHR are available on the UTHR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own UTHR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling UTHR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of UNITED THERAPEUTICS Corp's investment landscape.